Last reviewed 2026-05-28 · How we verify

Magnesium sulphate.

Magnesium sulphate. is a Electrolyte supplement / anticonvulsant / tocolytic agent Small molecule drug developed by Ain Shams University. It is currently FDA-approved for Seizure prophylaxis and treatment in eclampsia and preeclampsia, Acute asthma exacerbation, Cardiac arrhythmias (particularly torsades de pointes).

Magnesium sulphate acts as a physiological calcium antagonist and NMDA receptor antagonist, reducing neuromuscular excitability and vascular smooth muscle contractility.

Magnesium sulphate is a small molecule used in clinical trials for various conditions, including neuropathy, pain, recurrent breast carcinoma, stage IV breast cancer, and muscle relaxation. It has been compared to calcium gluconate and a placebo in these trials, suggesting its potential therapeutic effects.

At a glance

Mechanism of action

Magnesium ions compete with calcium for binding sites on voltage-gated calcium channels and block NMDA receptors, thereby decreasing neuromuscular transmission and reducing smooth muscle contraction. This mechanism underlies its use in preventing seizures in eclampsia/preeclampsia and in managing arrhythmias and acute asthma exacerbations. The drug also has vasodilatory properties that contribute to its therapeutic effects in hypertensive emergencies.

Approved indications

• Seizure prophylaxis and treatment in eclampsia and preeclampsia
• Acute asthma exacerbation
• Cardiac arrhythmias (particularly torsades de pointes)
• Hypertensive emergency
• Magnesium deficiency

Common side effects

• Flushing
• Hypotension
• Hypermagnesemia
• Loss of deep tendon reflexes
• Respiratory depression
• Muscle weakness

Key clinical trials

• The Relationship Between Opioid-Free Anesthesia and Postoperative Agitation-Delirium and Quality of Recovery in Pediatric Ear, Nose, and Throat Cases Monitored With Perioperative Bispectral Index
• Probiotic Treatment for Depression and Associated Mood Disorders in Parkinson's Disease (PHASE2)
• Opioid Free and Opioid Based Anesthesia in Elective Lumbar Spine Surgery
• Study to Evaluate the Efficacy, Safety, and Tolerability of Long-acting Intramuscular Cabotegravir and Rilpivirine for Maintenance of Virologic Suppression Following Switch From an Integrase Inhibitor in HIV-1 Infected Therapy Naive Participants (PHASE3)
• Comparison of Changes in Intra-myocardial Amino Acids During Use of Calafiore and Modified Del Nido Cardioplegia
• Comparison of Fentanyl and Magnesium to Control Reflex Hemodynamics in Patients Aged 50 and Older (NA)
• Biomarkers in Management of Post Partum Preeclampsia (PHASE4)
• Comparison of Mean Duration of Analgesia Following the Administration of Bupivacaine With and Without Magnesium Sulphate in Ultrasound Guided Erector Spinae Plane Block in Modified Radical Mastectomy Patients (NA)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• Magnesium sulphate. CI brief — competitive landscape report
• Magnesium sulphate. updates RSS · CI watch RSS
• Ain Shams University portfolio CI

Frequently asked questions about Magnesium sulphate.

Related

• Drug class: All Electrolyte supplement / anticonvulsant / tocolytic agent drugs
• Target: All drugs targeting Voltage-gated calcium channels, NMDA receptor
• Manufacturer: Ain Shams University — full pipeline
• Therapeutic area: All drugs in Obstetrics, Neurology, Gastroenterology, Emergency Medicine
• Indication: Drugs for Seizure prophylaxis and treatment in eclampsia and preeclampsia
• Indication: Drugs for Acute asthma exacerbation
• Indication: Drugs for Cardiac arrhythmias (particularly torsades de pointes)

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing